Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3086997
Max Phase: Preclinical
Molecular Formula: C34H63N7O5
Molecular Weight: 649.92
Molecule Type: Small molecule
Associated Items:
ID: ALA3086997
Max Phase: Preclinical
Molecular Formula: C34H63N7O5
Molecular Weight: 649.92
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCC(=O)N[C@@H](C)/C=C/C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)/C=C/C(=O)N[C@@H](CCCCN)C(N)=O
Standard InChI: InChI=1S/C34H63N7O5/c1-4-5-6-7-8-9-10-11-12-19-30(42)38-26(2)20-22-32(44)41-29(18-14-16-25-36)34(46)39-27(3)21-23-31(43)40-28(33(37)45)17-13-15-24-35/h20-23,26-29H,4-19,24-25,35-36H2,1-3H3,(H2,37,45)(H,38,42)(H,39,46)(H,40,43)(H,41,44)/b22-20+,23-21+/t26-,27-,28-,29-/m0/s1
Standard InChI Key: UTONXSNVVSRIFY-FAWLFVBVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 649.92 | Molecular Weight (Monoisotopic): 649.4891 | AlogP: 2.74 | #Rotatable Bonds: 28 |
Polar Surface Area: 211.53 | Molecular Species: BASE | HBA: 7 | HBD: 7 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 13.13 | CX Basic pKa: 10.51 | CX LogP: 2.32 | CX LogD: -2.89 |
Aromatic Rings: 0 | Heavy Atoms: 46 | QED Weighted: 0.05 | Np Likeness Score: 0.32 |
1. Shankar SS, Benke SN, Nagendra N, Srivastava PL, Thulasiram HV, Gopi HN.. (2013) Self-assembly to function: design, synthesis, and broad spectrum antimicrobial properties of short hybrid E-vinylogous lipopeptides., 56 (21): [PMID:24117107] [10.1021/jm400884w] |
Source(1):